Biotechnology

Why US equity investors should beware election soundbites and 'ill-conceived promises'

Trump and Clinton fight for presidency

27 June 2016 • 2 min read

George Robinson: My key lessons from investing in EMs and start-ups

Founding partner of Sloane Robinson

20 June 2016 • 8 min read

Short-term price action won't change underlying bio-pharma sector's values

Healthcare was one sector that did not fully participate in the recent stockmarket rally and finished the first quarter as the worst performer in the S&P 500 index, writes Legg Mason's Evan Bauman.

04 May 2016 • 2 min read

Woodford biotech holding admits 'material weakness' in finance controls

Shares dropped 90% since summer

03 May 2016 • 1 min read

Is the US election likely to challenge pharma and biotech sentiment further?

The pharmaceutical and biotechnology sector has performed well in recent years, primarily by virtue of attractive fundamentals.

20 April 2016 • 2 min read

The big turnaround stories of Q1... and the major sector laggards

Gold funds top performance charts

11 April 2016 • 3 min read

Is healthcare investment really best left until after the US election?

Biotech has fallen

29 March 2016 • 2 min read

Biotech valuations at their lowest for years

The biotechnology sector has been hit particularly hard by the risk-averse sentiment sweeping through global stock markets and after reaching a high in July 2015, the Nasdaq Biotechnology index shed about one-third of its value.

19 February 2016 • 2 min read